# Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Study · id `cardio:ct-nct07318610` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07318610](<https://clinicaltrials.gov/study/NCT07318610>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07318610

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7050 participants.

## Technical summary

Registry record NCT07318610. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-10 (actual); primary completion 2029-08-18 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7050 participants (planned count; ClinicalTrials.gov record NCT07318610, source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)
- Started: 2026-07-10 (actual) (ClinicalTrials.gov record NCT07318610, source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-08-18 (anticipated) (ClinicalTrials.gov record NCT07318610, source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)
- Completion: 2029-11-16 (anticipated) (ClinicalTrials.gov record NCT07318610, source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)
- Countries: United States; Japan; United Kingdom (ClinicalTrials.gov record NCT07318610, source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07318610-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
- Acronym: ROXI-PALISADE
- Condition: Peripheral Artery Disease (PAD)
- Intervention (Drug): REGN7508
- Intervention (Drug): REGN9933
- Intervention (Drug): Placebo
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 653bef5660ed60f380a4fd5c1a7348562113a179905295651832551f641a5a17
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
